CG Oncology (NASDAQ:CGON) Given New $79.00 Price Target at Royal Bank Of Canada

CG Oncology (NASDAQ:CGON) had its price target decreased by analysts at Royal Bank Of Canada from $81.00 to $79.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 6.59% from the company’s previous close.

A number of other research analysts also recently commented on the company. Wedbush increased their target price on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Truist Financial boosted their price target on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Wolfe Research started coverage on CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $83.18.

CG Oncology Stock Performance

Shares of CG Oncology stock traded down $0.73 during trading on Friday, reaching $74.11. The company had a trading volume of 284,638 shares, compared to its average volume of 1,158,647. The company has a market cap of $6.54 billion, a price-to-earnings ratio of -31.84 and a beta of 0.23. The firm’s fifty day moving average is $66.86 and its 200-day moving average is $63.87. CG Oncology has a fifty-two week low of $23.65 and a fifty-two week high of $77.00.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. On average, research analysts anticipate that CG Oncology will post -2.89 EPS for the current fiscal year.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 5,000 shares of CG Oncology stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director directly owned 5,000 shares in the company, valued at $350,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian Guan-Chyun Liu purchased 371,085 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were bought at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the transaction, the director directly owned 1,886,236 shares in the company, valued at $126,132,601.32. This represents a 24.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 37,129 shares of company stock valued at $2,663,817 in the last quarter. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in CGON. BlackRock Inc. bought a new stake in CG Oncology during the second quarter worth approximately $444,509,000. Deutsche Bank AG bought a new position in shares of CG Oncology in the second quarter valued at $14,033,000. TimesSquare Capital Management LLC acquired a new stake in shares of CG Oncology during the 2nd quarter valued at $14,983,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of CG Oncology during the 2nd quarter valued at $412,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of CG Oncology during the 2nd quarter worth $16,584,000. 26.56% of the stock is currently owned by institutional investors.

Key Stories Impacting CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets. Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, while Truist Financial also raised its target to $85 and reiterated a “buy” rating. Both targets imply approximately 14.7% upside from the referenced share price. Benzinga analyst coverage The Fly analyst coverage
• Positive Sentiment: HC Wainwright maintained a $100 “Buy” target. The firm raised its FY2030 EPS forecast to $6.88 from $6.77, reinforcing its view that CG Oncology could generate substantial long-term earnings as its business and pipeline develop. MarketBeat analyst estimates
• Neutral Sentiment: Options activity showed increased investor interest. Investors purchased a high volume of CGON call options, which may indicate bullish positioning, although options activity is speculative and does not necessarily reflect sustained buying of the stock. Investors buy CG Oncology call options
• Negative Sentiment: Second-quarter earnings missed expectations. CG Oncology reported a loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss reported a year earlier. The company’s $1.16 million in revenue exceeded the $0.36 million estimate, but the earnings shortfall likely weighs on near-term sentiment. CG Oncology second-quarter results
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS forecast to $2.34 from $2.43, partially offsetting its more optimistic FY2030 estimate and signaling some uncertainty in the timing of CG Oncology’s profitability.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.